Tuesday's top gainers include CervoMed, with key clinical trial catalysts ahead; Conexeu, which strengthened its leadership with board expansion; NeOnc, advancing its lead drug candidate into Phase 2 for aggressive brain tumours; and Simulations Plus, which is set to be acquired by Altaris affiliates, among others.